Cynvenio has a comprehensive translational approach to utilizing liquid biopsies. Our approach includes manufacturing open platforms and research reagents that analyze multiple templates (CTCs, cfDNA, germ line DNA, exosomes, platelets, specific targets such as PDL-1, Natural Killer Cells), multiple modalities (DNA, RNA, and protein), and multiple time-points. Cynvenio’s microfluidic technology has the unique capability of isolating rare templates with the highest purity in the industry. Because of our template purity, researchers are enabled perform downstream template (CTC) analysis with highly multiplex and sensitive technologies such as NGS without the need for whole genome amplification (sample to result in <48 hours). Cynvenio has developed and offers several tests through our CLIA/CAP lab or our partners such as Q2 Solutions.